Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

YOU MIGHT BE INTERESTED IN

  1. Statins: World Market Outlook 2011-2021

    Statins: World Market Outlook 2011-2021

    What does the future hold for the statins industry and market? Our new report shows how the patent expiry of Lipitor and others will affect statin drug revenues from 2011 onwards. In 2009 the world statins market generated over $27bn in revenues. We show the organisations, products and activities that will shape the statins industry and market this decade.

    ...more details
  2. World Generic Drug Market Outlook 2010-2025

    World Generic Drug Market Outlook 2010-2025

    Our new report will show you revenue prospects for the generic drug market from 2010 onwards. Where will the best growth prospects lie, and which companies will be the biggest winners? We provide revenue trends for 2010 to 2025 and discussions to meet your needs. You can have that report today, staying ahead.

    ...more details
  3. Global Cardiovascular Drugs Market 2009-2024

    Global Cardiovascular Drugs Market 2009-2024

    Cardiovascular disorders are leading causes of death worldwide. Cardiovascular therapeutics form a central part of the global pharmaceutical market, with a wide range of treatments, including leading blockbusters. As the patient population grows and cardiovascular diseases become more prevalent, cardiovascular drugs have the potential for continued sales growth in both mature and emerging markets.

    ...more details
  4. Antithrombotic/Anticoagulant Drugs: World Market Prospects 2010-2025

    Antithrombotic/Anticoagulant Drugs: World Market Prospects 2010-2025

    Our new report will show you how the market for antithrombotic and anticoagulant drugs will develop. You can indentify where the greatest opportunities will lie. There will be trends to watch from 2010 onwards, especially product launches and areas of revenue growth. You can have our report today, staying ahead.

    ...more details
  5. The US Pharmaceutical Market 2009-2024

    The US Pharmaceutical Market 2009-2024

    The United States has by far the world's largest pharmaceutical market. In the twelve months to Q2 2009, the US accounted for 41% of world pharmaceutical sales. Its vast economy, high standard of living, minimal pricing controls and strong intellectual property rights help make it the world's most dominant pharma market. The US also has one of the most stringent regulatory environments in the world. This brand new report - US Pharmaceutical Market 2009-2024 - will provide you with extensive information about the US pharma market and industry to benefit your work.

    ...more details
  6. Global Anti-Obesity Treatments Market 2010-2025

    Global Anti-Obesity Treatments Market 2010-2025

    Prevalence of obesity in the US and Europe has already reached high levels, with obesity being described as an epidemic and a "public health time-bomb". The developing world is also showing rising prevalence of obesity, now considered a serious - even life-threatening - disorder. In this report, we predict that the anti-obesity drug market will exhibit overall growth in worldwide revenues from 2010 to 2025, with new drugs entering the market during those years. Where will the best commercial prospects lie? Our new study provides the answers that you require.

    ...more details
  7. Clinical Trials: World Market 2010-2025

    Clinical Trials: World Market 2010-2025

    The market for clinical trial services has been expanding rapidly, with impressive revenue growth and expansion of the sector in recent years. Our new study shows how that sector will develop from 2010 onwards, with benefits to the pharma industry and clinical service providers. Clinical research organisations (CROs) are playing increasingly important roles in drug development worldwide, from conducting phase I trials to post-marketing studies.

    ...more details

PHARMA REPORT

rss_Pharma.jpg...see all
Statins: The World Market 2010-2025

Statins: The World Market 2010-2025

  • Publication date: 08/02/2010
  • Number of Pages: 133
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

Where will opportunities lie for these prominent drugs after Lipitor's patent expiry?

Statins are potent cholesterol-lowering drugs, making them important in the prevention of coronary heart disease. Consequently, statins constitute one of the most important sectors of the pharmaceutical industry, with total revenues exceeding $25 billion in 2009. Our new report - Statins: The World Market 2010-2025 - provides detailed sales predictions and supporting discussions for this important pharmaceutical sector.

The world statins market is facing rapid change. From 2010 onwards, there will be major patent expires – most notably for Lipitor - maturity of products, and rising competition from generic alternatives. What are the crucial drivers and restraints in this market? Where will the best opportunities lie for both original-branded and generic products? When will generic sales exceed branded? Who will be the new market leader? Statins: The World Market 2010-2025 answers those important questions and many others. This analytical report provides essential information to help you understand the statins market, with its marked commercial threats and opportunities this decade.

This report covers the following statins in detail, focussing on both commercial and therapeutic prospects from 2010 to 2025:
• Simvastatin
• Atorvastatin
• Pravastatin
• Rosuvastatin
• Fluvastatin
• Lovastatin
• Pitavastatin.

Comprehensive analysis of the world statins market

Statins: The World Market 2010-2025 critically examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 70 tables and figures included, as well as two original interviews with relevant experts. The result is a comprehensive market- and industry-centred study, with detailed analyses to benefit your work.

Why you should buy Statins: The World Market 2010-2025

In this report you will receive the following benefits in particular:
• You will assess the current market for statins
• You will analyse the statins market of the future, including a global sales forecast from 2010 to 2025, with informed discussions
• You will receive sales forecasts for leading brands and generic forms of statin drugs from 2010 to 2025, with detailed supporting information
• You will receive sales forecasts for the leading companies in the statins market from 2010 to 2015
• You will receive sales forecasts for leading geographical markets from 2010 to 2025, with regional characteristics covered
• You will examine commercial drivers and restraints in depth
• You will discover R&D pipeline developments in this sector
• You will read expert opinions from our original survey, with full interview transcripts.

You can obtain this report today

Nobody with an interest in the statins market should overlook this new market study. We forecast that there will be dramatic changes in this market area from 2010 onwards. This report provides essential information to help you take advantage of the statins market. Do you want to harness those opportunities? You can stay ahead by ordering this report today.

Do you want to harness those opportunities? You can stay ahead by ordering this report today.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary

2. Dyslipidemia and Coronary Heart Disease
2.1 Cholesterol and Triglycerides
2.2 Lipoproteins Transport Cholesterol and Triglycerides
2.3 Dyslipidemia and Atherosclerosis
2.4 Cholesterol Risk Levels
2.5 The Fredrickson/World Health Organization (WHO) Classification of Dyslipidemia
2.6 Cardiovascular Disease
2.7 CHD Risk Factors
2.8 Cholesterol Testing
2.9 Primary and Secondary Prevention of Atherosclerosis

3. Statins and Other Lipid-Lowering Drugs
3.1 Statins: Mechanism of Action and Types
3.2 Lovastatin
3.2.1 Lovastatin Indications
3.2.2 Lovastatin Brands and Generic Manufacturers
3.3 Simvastatin
3.3.1 Simvastatin Indications
3.4 Pravastatin
3.4.1 Pravastatin Indications
3.4.2 Pravastatin Brands and Generic Manufacturers
3.5 Fluvastatin
3.5.1 Fluvastatin Indications
3.5.2 Fluvastatin Brands and Generic Manufacturers
3.6 Atorvastatin
3.6.1 Atorvastatin Indications
3.6.2 Atorvastatin Brands and Generic Manufacturers
3.7 Rosuvastatin
3.7.1 Rosuvastatin Indications
3.7.2 Rosuvastatin Brands and Generic Manufacturers
3.8 Pitavastatin
3.9 Statin/Other Lipid-Lowering Drug Combinations
3.9.1 Lovastatin/Nicotinic Acid
3.9.2 Simvastatin/Nicotinic Acid
3.9.3 Simvastatin/Ezetimibe
3.9.4 Atorvastatin/Fenofibrate
3.9.5 Atorvastatin/Ezetimibe
3.9.6 Atorvastatin/Ezetimibe/Fenofibrate
3.10 Statin/Other Cardiovascular Drug Combinations
3.10.1 Caduet (Atorvastatin/Amlodipine)
3.10.2 Pravadual (Pravastatin/Aspirin)
3.10.3 Generic Statin/Other Cardiovascular Drugs
3.11 Other Dyslipidemia Drugs
3.11.1 Anion-Exchange Resins
3.11.2 Ezetimibe
3.11.3 Fibrates
3.11.4 Nicotinic Acid
3.11.5 Omega-3-Acid Ethyl Esters

4. The World Statins Market 2010-2025
4.1 Statins Dominate the Lipid-Regulating Drug Market
4.1.1 The World Lipid-Regulating Drug Market, 2009
4.1.2 World Lipid-Lowering Drug Market Sales Forecast, 2010-2025
4.2 The World Statin Market
4.2.1 The World Statin Market, 2009
4.2.2 World Statin Market Sales Forecast, 2010-2011
4.2.3 The Impact of Generic Atorvastatin on the World Statin Market, 2011-2014
4.2.4 World Statin Market Sales Forecast, 2015-2020
4.2.5 Prospects for the World Statin Market, 2020-2025
4.2.6 Statin Type Market Sales Forecast, 2010-2025
4.3 The Branded and Generic Statin Markets
4.3.1 The Branded and Generic Statin Markets, 2009
4.3.2 By 2019 Sales of Generic Statins Will Exceed Branded Revenues

5. Leading Statin Types and Products, 2010-2025
5.1 Atorvastatin
5.1.1 The Atorvastatin Market in 2009
5.1.2 Atorvastatin Market Sales Forecast, 2010-2025
5.1.3 Lipitor/Prevencor/Totalip Market Sales Forecast, 2010-2011
5.1.4 Lipitor/Prevencor/Totalip Market Sales Forecast, 2011-2015 - The Ultimate Patent Cliff?
5.1.5 Lipitor/Prevencor/Totalip Market Sales Forecast, 2015-2025
5.1.6 Generic Atorvastatin Market Sales Forecast, 2010-2025
5.2 Rosuvastatin
5.2.1 The Rosuvastatin Market in 2009
5.2.2 Rosuvastatin Market Sales Forecast, 2009-2024
5.2.3 Crestor Market Sales Forecast, 2010-2015
5.2.4 Crestor Market Sales Forecast, 2015-2025
5.2.5 Generic Rosuvastatin Market Sales Forecast, 2010-2025
5.3 Simvastatin
5.3.1 The Simvastatin Market in 2009
5.3.2 Simvastatin Market Sales Forecast, 2010-2025
5.3.3 Zocor Market Sales Forecast, 2010-2025
5.3.4 Generic Simvastatin Market Sales Forecast, 2010-2025
5.4 Pravastatin
5.4.1 The Pravastatin Market in 2009
5.4.2 Pravastatin Market Sales Forecast, 2010-2025
5.4.3 Mevalotin/Pravachol Market Sales Forecast, 2010-2025
5.4.4 Generic Pravastatin Market Sales Forecast, 2010-2025
5.5 Fluvastatin
5.5.1 The Fluvastatin Market in 2009
5.5.2 Fluvastatin Market Sales Forecast, 2010-2025
5.5.3 Lescol Market Sales Forecast, 2010-2025
5.5.4 Generic Fluvastatin Market Sales Forecast, 2010-2025
5.6 Pitavastatin
5.6.1 The Pitavastatin Market in 2009
5.6.2 Pitavastatin Market Sales Forecast, 2010-2025
5.7 Lovastatin
5.7.1 The Lovastatin Market in 2009
5.7.2 Lovastatin Market Sales Forecast, 2010-2025
5.8 Statin/Non-Statin Combination Drugs
5.8.1 The Statin/Non-Statin Combination Drug Market in 2009
5.8.2 Statin/Non-Statin Combination Drugs, 2010-2015
5.8.3 Statin/Non-Statin Combination Drugs, 2015-2025
5.8.4 Vytorin Market Sales Forecast, 2010-2025
5.8.5 Caduet Market Sales Forecast, 2010-2025

6. Leading Statin Manufacturers, 2010
6.1 Five Players Controlled 85% of the Statin Market in 2009
6.2 Pfizer's Statin Revenues Sales Forecast, 2010-2015
6.3 A New Leading Statin Manufacturer by 2013
6.4 Merck & Co Statin Revenues Sales Forecast, 2010-2015

7. Issues Affecting the Statin Industry
7.1 SWOT Analysis of the Statin Industry
7.2 Patient Compliance
7.2.1 Patients on Statins Exhibit Poor Patient Compliance
7.2.2 Effective Contact between Patients and Healthcare Practitioners is the Key to Improving Patient Compliance
7.2.3 Developments in Cholesterol Testing
7.2.4 Diagnostic Testing for Genetic Markers May Increase Patient Compliance
7.2.5 Increasing Use of Web-Based Information Technology Will Improve Patient Compliance
7.3 Generic Statins
7.3.1 Expected Patent Expiries in the Statin Market
7.3.2 Governments and Insurers Will Favour Generic Statins
7.4 Statin Clinical Trials
7.5 Safety of Statins
7.6 Statin OTC Switching
7.6.1 The Rationale for OTC Switching
7.6.2 Statin OTC Switching in the UK
7.6.3 Statin OTC Switching in the US
7.6.4 What are the Worldwide Prospects for Statin OTC Switching?
7.7 Prevalence of Coronary Heart Disease
7.7.1 Coronary Heart Disease is the Leading Cause of Death Worldwide
7.7.2 Future Projections for Prevalence of Coronary Heart Disease
7.7.3 The Economic Cost of Coronary Heart Disease
7.8 Promising Non-Statin Lipid-Lowering Pipeline
7.8.1 Statins Cannot Treat All Forms of Dyslipidemia
7.8.2 Developments in Existing Rivals for Statins
7.8.2.1 Novel Nicotinic Acid Formulations
7.8.2.2 New Formulation of Fibrates
7.8.2.3 Omega-3 Fatty Acids
7.8.2.4 Functional Foods and Nutritional Supplements
7.8.3 Novel Lipid-Lowering Agents
7.8.3.1 CETP Inhibitors
7.8.3.2 Cholesterol Absorption Inhibitors
7.8.3.3 Antisense Oligonucleotides
7.8.3.4 PPAR-Alpha Agonists
7.8.3.5 MTP Inhibitors
7.8.3.6 Phospholipase A2 Inhibitors
7.8.3.7 Nicotinic Acid Receptor Agonists
7.8.3.8 Human Antibodies

8. Interviews with Relevant Experts
8.1 Humayun J. Chaudhry, D.O., M.S., FACP, Commissioner of Health Services, Suffolk County, New York
8.1.1 Improving Patient Compliance in Statin Therapy
8.1.2 The Future of Cholesterol Testing
8.1.3 Web-Based Information Technology in Statin Prescribing
8.2 Amir Shroufi, PhD, Cambridge Institute of Public Health
8.2.1 The Importance of Improving Patient Adherence (Compliance) in Statin Therapy
8.2.2 Methods of Improving Patient Adherence
8.2.3 Limitations of Using Statins to Lower Cholesterol
8.2.4 Unmet Needs
8.2.5 Challenges for Research into Patient Adherence

9. Statin Country Markets, 2010-2025
9.1 Leading Country Markets in 2009
9.2 Leading Country-Market Sales Forecasts, 2010-2025
9.3 The US Statin Market
9.3.1 The US Statin Market in 2009
9.3.2 US Statin Market Sales Forecast, 2010-2015
9.3.3 US Statin Market Sales Forecast, 2015-2025
9.4 The Japanese Statin Market
9.4.1 The Japanese Statin Market in 2009
9.4.2 Japanese Statin Market Sales Forecast, 2010-2025
9.5 The Canadian Statin Market
9.6 European Statin Markets, 2010-2025
9.7 Emerging Statin Markets: China and India

10. The Statin R&D Pipeline
10.1 The Statin Pipeline Lacks Enough New Drug Candidates
10.2 New Statins and Statin Combination Drugs in Development
10.2.1 Crestor/TriLipix
10.2.2 Simvastatin and Nicotinic Acid and Laropiprant
10.2.3 Pravastatin and Fenofibrate Combination Therapy
10.2.4 Simvastatin and Fenofibrate Combination Therapy
10.2.5 Simvastatin/Rosiglitazone
10.2.6 PPD Statin/RBx 10558
10.2.7 NCX 6560

11. Conclusions
11.1 The Statin Market in 2009
11.2 Future Challenges for the Statin Industry
11.3 World Statin Market Sales Forecast, 2010-2025
11.4 Prospects for Leading Statin Manufacturers and Country Markets

List of Tables
Table 2.1 Risk Levels for Total Cholesterol
Table 2.2 Risk Levels for LDL Cholesterol
Table 2.3 Risk Levels for HDL Cholesterol
Table 2.4 Risk Levels for Triglycerides
Table 2.5 The Fredrickson/WHO Classification of Dyslipidemia
Table 3.1 Leading Generic Lovastatin Manufacturers, 2009
Table 3.2 Leading Generic Simvastatin Manufacturers, 2009
Table 3.3 Leading Generic Pravastatin Manufacturers, 2009
Table 3.4 Branded Fibrates, 2009
Table 3.5 Leading Prescription Omega-3 Acid Products, 2009
Table 4.1 World Lipid-Lowering Drug Market, 2009
Table 4.2 World Lipid-Lowering Drug Market Sales Forecasts, 2010-2016
Table 4.3 World Lipid-Lowering Drug Market Sales Forecasts, 2017-2025
Table 4.4 Leading Statin Types and Brands: Sales and Market Shares, 2009
Table 4.5 Statin Drugs: Market Sales Forecasts, 2010-2016
Table 4.6 Statin Drugs: Market Sales Forecasts, 2017-2025
Table 4.7 The Branded and Generic Statin Markets: Sales and Market Shares, 2009
Table 4.8 Branded and Generic Statin Market Sales Forecasts, 2010-2016
Table 4.9 Branded and Generic Statin Market Sales Forecasts, 2017-2025
Table 5.1 Atorvastatin Market: Sales and Market Shares, 2009
Table 5.2 Atorvastatin Drug Sales Forecasts, 2010-2016
Table 5.3 Atorvastatin Drug Sales Forecasts, 2017-2025
Table 5.4 Rosuvastatin: Sales and Market Shares, 2009
Table 5.5 Rosuvastatin Drug Sales Forecasts, 2010-2016
Table 5.6 Rosuvastatin Drug: Sales Forecasts, 2017-2025
Table 5.7 Smivastatin Market: Sales and Market Shares, 2009
Table 5.8 Simvastatin Drug Sales Forecasts, 2010-2016
Table 5.9 Simvastatin Drug Sales Forecasts, 2017-2025
Table 5.10 Pravastatin Market: Sales and Market Shares, 2009
Table 5.11 Pravastatin Drug Sales Forecasts, 2010-2016
Table 5.12 Pravastatin Drug Sales Forecasts, 2017-2025
Table 5.13 Fluvastatin Drug Sales Forecasts, 2010-2016
Table 5.14 Fluvastatin Drug Sales Forecasts, 2017-2025
Table 5.15 Pitavastin Sales Forecast, 2010-2016
Table 5.16 Pitavastin Sales Forecast, 2017-2025
Table 5.17 Lovastatin Sales Forecast, 2010-2016
Table 5.18 Lovastatin Sales Forecast, 2017-2025
Table 5.19 Statin and Statin/Non-Statin Combination Drugs: Sales and Market Shares, 2009
Table 5.20 Statin/Non-Statin Combination Drug: Sales and Market Shares, 2009
Table 5.21 Statin/Non-Statin Combination Drug Sales Forecasts, 2010-2016
Table 5.22 Statin/Non-Statin Combination Drug Sales Forecasts, 2017-2025
Table 6.1 Leading Statin Manufacturers: Sales and Market Shares, 2009
Table 6.2 Leading Statin Manufacturers: Revenue Sales Forecasts, 2010-2015
Table 7.1 SWOT Chart for the Statins Industry, 2010-2025
Table 7.2 Expected Statin Patent Expiry Dates, 2010-2025
Table 9.1 Leading Statin Country Markets: Sales and Market Shares, 2009
Table 9.2 Leading Statin Country-Market Sales Forecasts, 2010-2016
Table 9.3 Leading Statin Country-Market Sales Forecasts, 2017-2025
Table 10.1 The Statin R&D Pipeline, 2009

List of Figures
Figure 4.1 World Lipid Lowering Drug Market Sales Forecast, 2010-2025
Figure 4.2 Statin Type Market Shares, 2009
Figure 4.3 Leading Statin Brands: Market Shares, 2009
Figure 4.4 World Statin Market Sales Forecast, 2010-2025
Figure 4.5 Statin Type Market Sales Forecast, 2010-2025
Figure 4.6 Statin Type Market Shares, 2015
Figure 4.7 Statin Type Market Shares, 2020
Figure 4.8 Statin Type Market Shares, 2025
Figure 4.9 Branded and Generic Statin Market Sales Forecasts, 2010-2025
Figure 5.1 Atorvastatin Drugs: Market Sales Forecasts, 2010-2025
Figure 5.2 Rosuvastatin Drugs: Market Sales Forecasts, 2010-2025
Figure 5.3 Simvastatin Drugs: Market Sales Forecasts, 2010-2025
Figure 5.4 Pravastatin Drugs: Market Sales Forecasts, 2010-2025
Figure 5.5 Fluvastatin Drugs: Market Sales Forecasts, 2010-2025
Figure 5.6 Pitavastin Market Sales Forecast, 2010-2025
Figure 5.7 Lovastatin Market Sales Forecast, 2010-2025
Figure 5.8 Statin Combination Drug Sales Forecasts, 2010-2025
Figure 6.1 Leading Statin Manufacturers: Market Shares, 2009
Figure 6.2 Leading Statin Manufacturers: Revenue Sales Forecasts, 2010-2015
Figure 9.1 Statin Market Shares by Country, 2009
Figure 9.2 Statin Market Shares by Country, 2015
Figure 9.3 Statin Market Shares by Country, 2020
Figure 9.4 Statin Market Shares by Country, 2025
Figure 9.5 US Statin Market Sales Forecast, 2010-2025
Figure 9.6 Japanese, European and Canadian Statin Market Sales Forecasts, 2010-2025
Figure 9.7 China & India Statin Market Sales Forecasts, 2010-2025 

Companies Listed

Abbott
Almirall
American Heart Association
Apotex
AstraZeneca
Astellas
Atherotech
Bagó
Bayer
Biovail
Bristol-Myers Squibb
Cambridge Institute of Public Health
Celera
Chiesi
Choongwae
Daiichi Sankyo
Dr. Reddy's Laboratories
Esteve
European Medicines Agency (EMEA)
Ferrer
Food and Drug Administration (FDA)
Galephar
Genzyme
GlaxoSmithKline (GSK)
Kissei
Kowa
Liposcience
Lupin
Menarini
Merck & Co.
Micro Labs
Mitsubishi Tanabe
Mylan
NicOx
Nissan Chemical
Novartis
Pierre Fabre Co.
Pfizer
PPD
Ranbaxy
Ratiopharm
Recordati
Sanofi-Aventis
Schering-Plough
Sciele (a wholly-owned subsidiary of Shionogi)
Sepracor
Shionogi
Solvay
Teva
Welchol
World Health Organization (WHO) 

 

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close